RTW Biotech Opportunities reported a July NAV of $2.82 per share, down 1.6% for the month, compared with declines of 1.7% for the Nasdaq Biotech Index and 4.4% for the..
RTW Biotech Opportunities reported NAV per ordinary share of US$2.61 at 31 May 2026, up 0.6% for the month, with annualised NAV performance of 14.4% since launch...
RTW Bio reported an unaudited NAV of US$2.59 per share at 30 April 2026, up 7.0% for the month, supported by strong performance from Kailera and other portfolio holdings amid..
RTW Biotech Opportunities has participated in Windward Bio’s $165 million crossover financing, supporting development of long-acting immunology therapies including asthma and COPD candidate WIN378...
Kailera Therapeutics priced a $625 million Nasdaq IPO, marking the largest biotech listing by proceeds and delivering a significant valuation uplift for RTW Biotech Opportunities...
RTW Biotech Opportunities Ltd reported an unaudited NAV of $2.41 per share as of 28 February 2026, up 1.7% for the month. Biotech equities outperformed broader markets amid sector rotation..
RTW Biotech Opportunities Ltd announces that Boston Scientific Corporation has agreed to acquire Penumbra, Inc., a public portfolio company, in a transaction valued at $14.5 billion...
RTW Biotech Opportunities reported a July NAV of $2.82 per share, down 1.6% for the month, compared with declines of 1.7% for the Nasdaq Biotech Index and 4.4% for the Russell 2000 Biotech Index. Since launch, NAV per share has delivered 15.3% annualised performance...
RTW Biotech Opportunities reported NAV per ordinary share of US$2.61 at 31 May 2026, up 0.6% for the month, with annualised NAV performance of 14.4% since launch...
RTW Bio reported an unaudited NAV of US$2.59 per share at 30 April 2026, up 7.0% for the month, supported by strong performance from Kailera and other portfolio holdings amid rising biotech IPO and M&A activity...
RTW Biotech Opportunities has participated in Windward Bio’s $165 million crossover financing, supporting development of long-acting immunology therapies including asthma and COPD candidate WIN378...
Kailera Therapeutics priced a $625 million Nasdaq IPO, marking the largest biotech listing by proceeds and delivering a significant valuation uplift for RTW Biotech Opportunities...
RTW Biotech Opportunities Ltd reported an unaudited NAV of $2.41 per share as of 28 February 2026, up 1.7% for the month. Biotech equities outperformed broader markets amid sector rotation and improved capital markets activity...
RTW Biotech Opportunities Ltd announces that Boston Scientific Corporation has agreed to acquire Penumbra, Inc., a public portfolio company, in a transaction valued at $14.5 billion...
